Solitary plasmacytoma — VA Rating Criteria (38 CFR DC 7724)

The VA rates Solitary plasmacytoma under Diagnostic Code 7724 at the following tiers: 100%. The minimum 100% rating requires: Solitary plasmacytoma, when there is active disease or during a treatment phase. The maximum 100% rating requires: Solitary plasmacytoma, when there is active disease or during a treatment phase.

Diagnostic Code 7724 is the VA rating identifier for Solitary plasmacytoma within 38 CFR 38 CFR § 4.117. It defines the specific symptom criteria and percentage thresholds a VA adjudicator uses to assign a disability rating. The diagnostic code is listed on a veteran's rating decision letter.

The highest schedular rating for Solitary plasmacytoma under DC 7724 is 100%. This tier requires: Solitary plasmacytoma, when there is active disease or during a treatment phase. Veterans who cannot secure substantially gainful employment due to Solitary plasmacytoma alone or in combination with other service-connected conditions may also qualify for TDIU at the 100% compensation rate under 38 CFR § 4.16.

Solitary plasmacytoma is rated under 38 CFR 38 CFR § 4.117, Diagnostic Code 7724. This section is part of the Schedule for Rating Disabilities (38 CFR Part 4) and can be read in full at the eCFR website.

Secondary conditions caused or aggravated by Solitary plasmacytoma may be ratable under 38 CFR § 3.310. Veterans should work with a VSO or accredited claims agent to document the medical relationship.

Service connection for Solitary plasmacytoma requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease that may have caused or aggravated it, and (3) a medical nexus connecting the current diagnosis to that in-service event. A nexus letter from a treating physician or independent medical examiner is the most reliable nexus evidence. C&P exam findings can also establish nexus if adequately documented.